补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响

doi:10.12092/j.issn.1009-2501.2018.06.016

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (6): 694-699.doi: 10.12092/j.issn.1009-2501.2018.06.016

补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响

郑青秀，徐小小，刘刚，马晓东

温州市中医院呼吸内科，温州 325000，浙江

收稿日期:2017-11-17 修回日期:2018-01-12 出版日期:2018-06-26 发布日期:2018-06-19
作者简介:郑青秀，女，本科，主治医师，研究方向：呼吸疾病的治疗。 Tel：15968786867 E-mail：zqx171116@163.com
基金资助:
温州市科技局公益性项目（Y20160094）

Effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis

ZHENG Qingxiu，XU Xiaoxiao，LIU Gang，MA Xiaodong

Department of Respiratory Medicine，Wenzhou Hospital of Traditional Chinese Medicine (TCM) ，Wenzhou 325000，Zhejiang，China

Received:2017-11-17 Revised:2018-01-12 Online:2018-06-26 Published:2018-06-19

摘要/Abstract

摘要：

目的：探讨补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响。方法：将60例气虚血瘀型肺癌患者分为观察组和对照组。对照组采用常规营养支持治疗。观察组在对照组基础上，给予补阳还五汤治疗。采用卡式评分（KPS评分）评估患者的生存质量的变化；采用中医症状评分评估患者的中医症状疗效；检测两组患者治疗前后血液流变学指标（全血黏度、血浆黏度、红细胞压积、纤维蛋白原、血小板）的水平；检测两组患者治疗前及治疗后7、14、28 d的血清组织型纤溶酶原激活物（tissue plasminogen activator, tPA）、纤溶酶原激活物抑制物-1（plasminogen activatinhibitor 1，PAI1）的水平。记录两组患者治疗过程中肺栓塞的发生情况。结果: 观察组的卡氏评分的疗效明显高于对照组，差异具有统计学意义（P<0.05）；观察组的中医症状评分的疗效明显高于对照组，差异有统计学意义（P<0.05）；观察组治疗后的全血黏度、血浆黏度、红细胞压积、纤维蛋白原、血小板明显降低，且上述指标明显低于对照组，差异均有统计学意义（P<0.05）；治疗28 d后，观察组的tPA明显升高，且明显高于对照组，PAI1明显降低，且明显低于对照组，差异有统计学意义（P<0.05）；观察组肺栓塞发生率低于对照组，但差异无统计学意义（P>0.05）。结论：补阳还五汤能显著改善气虚血瘀型肺癌患者的血液高凝状态，改善患者的生存质量。

关键词: 补阳还五汤, 气虚血瘀型, 肺癌, 高凝状态

Abstract:

AIM: To investigate the effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis type. METHODS: Sixty cases of lung cancer patients with Qi deficiency and blood stasis were divided into observation group and control group. The control group was treated with routine nutritional support. The observation group was given Buyanghuanwu decoction on the basis of the control group. The KPS score was recorded to assess the quality of life of the patients. Symptoms of Chinese medicine were evaluated by TCM symptom score. Blood rheology indexes (whole blood viscosity, plasma viscosity, hematocrit, fibrinogen and platelet) were detected before and after treatment of the two groups. The levels of serum tPA and PAI-1 were detected before and after treatment 7, 14, 28 d in two groups. The incidence of pulmonary embolism in the two groups was recorded during the treatment.RESULTS:The curative effect of the observation group was significantly higher than that of the control group. The difference was statistically significant (P<0.05). The curative effect of TCM symptom score in the observation group was significantly higher than that in the control group. The difference was statistically significant (P<0.05). The whole blood viscosity, plasma viscosity, hematocrit, fibrinogen and platelets were significantly decreased after treatment in the observation group. And the above indexes were significantly lower than that of the control group. The difference was statistically significant (P<0.05). After 28 d of treatment, the tPA in the observation group was significantly higher than that of the control group. PAI-1 was significantly lower than that of the control group. The difference was statistically significant (P<0.05). The incidence of pulmonary embolism in the observation group was lower than that in the control group. But the difference was not statistically significant (P>0.05). CONCLUSION: Buyanghuanwu decoction can significantly improve the hypercoagulable state of patients with Qi deficiency and blood stasis type lung cancer, and improve the quality of life of patients.

Key words: Buyanghuanwu decoction, Qi deficiency and blood stasis type, lung cancer, hypercoagulable state

中图分类号:

R734.2

郑青秀，徐小小，刘刚，马晓东. 补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响[J]. 中国临床药理学与治疗学, 2018, 23(6): 694-699.

ZHENG Qingxiu，XU Xiaoxiao，LIU Gang，MA Xiaodong. Effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 694-699.

参考文献

［1］韩啸东, 张侠, 刘畅,等. 非小细胞肺癌患者血液高凝状态的临床调查［J］. 现代生物医学进展, 2015, 15(5):882-886.
［2］何佩珊, 杨公博, 潘国凤,等. 老年非小细胞肺癌患者围手术期证型变化及防治策略［J］. 华中医药杂志, 2017, 32(3):1057-1059.
［3］张红, 尹秀东, 李祥. 补阳还五汤加味配合头部伽玛刀治疗气虚血瘀型肺癌脑转移的临床观察［J］. 中医药导报, 2017, 23(2):49-50.
［4］支修益，吴一龙，马胜林，等.原发性肺癌诊疗规范(2011版)［J］.中国肺癌杂志，2012，15(12)：677-688.
［5］Detterheck FC, Boffa DJ,fanoue LT.fhe new lung cancer staging system［J］.Chest,2009,136(1):260-271.
［6］国家食品药品监督管理总局.中药新药临床研究指导原则(试行)［S］.北京:中国医药科学出版社，2002:216-221.
［7］孙燕.临床肿瘤内科手册第三版［M］. 北京:人民卫生出版社, 1987:53-54.
［8］王静, 张侠. 恶性肿瘤患者高凝状态的危险因素、发生机制及实验室检测［J］.检验医学与临床, 2015, 12(15):2284-2287.
［9］闫绍辉, 王栋, 李湘红,等.恶性肿瘤患者高凝状态与血栓形成的临床研究［J］.中国肿瘤临床与康复, 2014, 21(5):542-544.
［10］韩燕, 杨国旺, 王笑民. 晚期非小细胞肺癌中医证候分布及组合规律文献研究［J］. 北京中医药, 2014, 33(3):175-178.
［11］逄艳, 张芳. 补阳还五汤改善晚期肺癌高凝状态的临床研究［J］. 云南中医中药杂志, 2017, 38(7):33-34.
［12］王冬梅, 施怡, 姚新颖,等. 益气活血膏方与补阳还五汤颗粒对气虚血瘀证患者血液流变学影响比较［J］. 世界中医药, 2014, 9(10):1296-1297.
［13］黄兴, 李艳芬, 寇冠军,等. 补阳还五汤抗动脉粥样硬化作用机制研究进展［J］. 中华中医药杂志, 2017, 32(3):1187-1190.
［14］李鸿波, 许启霞. 晚期肺癌患者凝血纤溶系统的变化及化疗对其的影响［J］. 肿瘤防治研究, 2014, 41(7):766-770.
［15］刘明, 周承志, 欧阳铭. 尿激酶型纤溶酶原激活物抑制剂1参与非小细胞肺癌的侵袭与转移［J］. 国际呼吸杂志, 2015, 35(12):881-885.

[1]	游蓉丽, 黄玉荣, 毛睿, 海丽娜, 王颖莉, 王艳. 基于血清代谢组学与网络药理学探究复方苦参注射液治疗肺癌的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(9): 988-999.
[2]	付婷, 李芳, 潘大燕, 夏园园, 张秋园. 肺癌细胞外泌体来源的miR-718通过靶向PTEN诱导血管新生的研究[J]. 中国临床药理学与治疗学, 2023, 28(6): 624-632.
[3]	李菲, 丁慧琴, 陈梦静. 异莲心碱激活ERK信号通路诱导肺癌PC9细胞自噬的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1235-1240.
[4]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[5]	苏洋, 周峰, 丁金磊. 艾司氯胺酮复合舒芬太尼对胸腔镜肺癌根治术后情绪及镇痛的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 59-65.
[6]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[7]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[8]	王琳, 李重阳, 李帅虎, 高盛涵, 徐甜, 李飞. 肺癌中致病融合基因的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 877-885.
[9]	赵子文, 范方田, 蒋志君. 诱导性支气管相关淋巴组织（iBALT）形成与相关肺疾病的研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 353-360.
[10]	崔华, 燕红霞, 尹梅. 下调lncRNA LINC00176对肺癌A549/DDP细胞顺铂耐药和自噬的影响[J]. 中国临床药理学与治疗学, 2021, 26(6): 616-623.
[11]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[12]	裴清华, 孙建立. 奥希替尼获得性耐药的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 105-112.
[13]	魏为添, 陈晟, 汪亮, 曾剑. 灯盏花素对非小细胞肺癌A549细胞的促凋亡作用[J]. 中国临床药理学与治疗学, 2020, 25(6): 618-624.
[14]	杨国良, 胡丹丹, 徐一凯, 楼黎明. 益气活血汤通过miR-21/PTEN信号通路抑制肺癌细胞恶性生物学行为[J]. 中国临床药理学与治疗学, 2020, 25(5): 512-518.
[15]	毛曦轲, 喻辰晞, 黄滔, 毛桐俊, 吴志浩. 内质网应激及其在肺癌中作用的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(10): 1160-1170.

补阳还五汤对气虚血瘀型肺癌患者血液高凝状态的影响

Effects of Buyanghuanwu decoction on blood hypercoagulability in lung cancer patients with Qi deficiency and blood stasis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价